focus -WSS

focus

author：fashion 2025-09-06 02:16:22 - browse：72522

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Oak trusses raised to roof of fire

explore

WSS

Tome Biosciences co

Congress might make insulin pumps more accessible to the blind

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Why ADHD is under

It's time to get medical device identifiers over the finish line

Juul documents reveal insider tactics on political lobbying

explore

focus

focus

As demand for Covid shots wanes, Moderna seeks its next success

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Guidelines to prevent youth baseball injuries need more muscle

Resistance to opioid

Anesthesiologist group: stop taking Ozempic before surgery

Latigo launches with $135 million for Vertex

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why Eli Lilly’s earnings didn’t quite live up to the hype

The cancer drug shortage isn’t new — and neither are the solutions

Palantir health business leans on meeting customers’ needs

hotspot

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Oak trusses raised to roof of fire

N.Y. state detects polio case, first in the U.S. since 2013

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Ebola vaccine can save some who are already sick, per new study

Lecanemab for Alzheimer's is coming. Is the health system ready?

focus

knowledge

explore

focus